ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,277.51
0.80%
Dow Jones
38,686.32
1.51%
US Dollar vs MXN
16.99024
-0.30%
Brent Oil
81.295
0.00%
Bitcoin
67,649.69
0.25%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NYSE
  6. Merck and Co Inc (MRK)

  7. Merck and Co Inc (MRK) Noticias

MRK

Merck (MRK)

Merck and Co Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NYSE:MRK
FechaHoraFuenteTítuloSímboloCompañía
30/05/202415:39Edgar (US Regulatory)Form CERT - Certification by an exchange approving securities for listingNYSE:MRKMerck and Co Inc
30/05/202415:28Edgar (US Regulatory)Form 8-A12B - Registration of securities [Section 12(b)]NYSE:MRKMerck and Co Inc
30/05/202415:14Edgar (US Regulatory)Form 8-K - Current reportNYSE:MRKMerck and Co Inc
29/05/202408:10IH Market NewsRising Treasury Yields May Weigh On Wall StreetNYSE:MRKMerck and Co Inc
29/05/202406:34IH Market NewsRobinhood Shares Surge 3.3% on Stock Buyback Announcement; Anglo Declines BHP Deadline Extension, and More NewsNYSE:MRKMerck and Co Inc
29/05/202406:15Business WireFDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural MesotheliomaNYSE:MRKMerck and Co Inc
29/05/202405:45Business WireMerck to Acquire EyeBioNYSE:MRKMerck and Co Inc
28/05/202415:44IH Market NewsNasdaq Climbs To Another Record Closing High But Dow Sees Further DownsideNYSE:MRKMerck and Co Inc
28/05/202415:31Edgar (US Regulatory)Form SD - Specialized disclosure reportNYSE:MRKMerck and Co Inc
28/05/202414:12Business WireMerck Announces Third-Quarter 2024 DividendNYSE:MRKMerck and Co Inc
28/05/202405:45Business WireMerck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)NYSE:MRKMerck and Co Inc
20/05/202405:28Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:MRKMerck and Co Inc
16/05/202415:15Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNYSE:MRKMerck and Co Inc
15/05/202410:31Edgar (US Regulatory)Form POSASR - Post-effective Amendment to an automatic shelf registration statementNYSE:MRKMerck and Co Inc
15/05/202405:45Business WireMerck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse PipelineNYSE:MRKMerck and Co Inc
13/05/202405:45Business WireMerck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk MelanomaNYSE:MRKMerck and Co Inc
09/05/202406:05PR Newswire (Canada)Santé Canada approuve KEYTRUDA® pour le traitement, en association avec une chimiothérapie à base de gemcitabine, des adultes atteints d'un carcinome des voies biliaires non résécable localement avancé ou métastatiqueNYSE:MRKMerck and Co Inc
09/05/202406:05PR Newswire (Canada)Health Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapyNYSE:MRKMerck and Co Inc
09/05/202405:45Business WireMerck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative IntentNYSE:MRKMerck and Co Inc
08/05/202405:45Business WireMerck to Participate in the Bank of America Securities 2024 Healthcare ConferenceNYSE:MRKMerck and Co Inc
06/05/202415:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:MRKMerck and Co Inc
06/05/202415:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:MRKMerck and Co Inc
01/05/202406:15Business WireMerck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaNYSE:MRKMerck and Co Inc
29/04/202408:00Business WireMerck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for AdultsNYSE:MRKMerck and Co Inc
25/04/202415:40IH Market NewsU.S. Stocks Climb Well Off Worst Levels But Close Mostly LowerNYSE:MRKMerck and Co Inc
25/04/202408:09IH Market NewsFutures Pointing To Sharply Lower Open On Wall StreetNYSE:MRKMerck and Co Inc
25/04/202406:52IH Market NewsSouthwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on EarningsNYSE:MRKMerck and Co Inc
25/04/202405:30Business WireMerck Announces First-Quarter 2024 Financial ResultsNYSE:MRKMerck and Co Inc
19/04/202406:04PR Newswire (Canada)Santé Canada approuve KEYTRUDA® comme traitement de première intention, en association avec une chimiothérapie à base de fluoropyrimidine et de platine, des adultes atteints d'un adénocarcinome gastrique ou de la jonction gastro-œsophagienne (JGO) HNYSE:MRKMerck and Co Inc
19/04/202406:04PR Newswire (Canada)Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-contaNYSE:MRKMerck and Co Inc
 Showing the most relevant articles for your search:NYSE:MRK

Su Consulta Reciente

ASX
AQXOC
Alice Queen
NYSE
IBP
Installed Building Produ...
BITV
SOLEUR
Solana
BOV
SUZB3Q
SUZANO PAPEL ON
NASDAQ
CLSK
CleanSpark
ASX
ANVHAD
AusNet Services
NYSE
UBS
UBS
TSX
LGT.B
Logistec
NASDAQ
RAPT
RAPT Therapeutics
NYSE
BABA
Alibaba
TSX
BN
Brookfield
NYSE
EXK
Endeavour Silver
BOV
PLAS3
PLASCAR PART ON
BOV
RAIL3
RUMO S.A ON
TG
6CQ
Cresco Labs
ASX
AYM
Australia United Mining
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados